Assessment | Page 44 of 49 | SpiritIndia.com

Health :: UC San Diego Supercomputers Help Speed High-Tech Drug Design

The high-stakes task of designing new drugs relies on high-tech tools, especially computerized, three-dimensional simulations of proteins. Researchers at the San Diego Supercomputer Center (SDSC), contributing their massive computational capabilities to a collaboration with colleagues at the University of Washington (UW) and IBM, have helped to achieve the largest-ever protein-structure prediction – and completed the complex simulation in less than three hours.

Ecology :: Stern Review on the Economics of Climate change

The most comprehensive review ever carried out on the economics of climate change was published today. The Review, which reports to the Prime Minister and Chancellor, was commissioned by the Chancellor in July last year. It has been carried out by Sir Nicholas Stern, Head of the Government Economic Service and former World Bank Chief Economist.

Health :: NYU Medical Center ranked in the top 50 hospitals

Fifty U.S. hospitals, including NYU Medical Center, have been named to the first Leapfrog Top Hospitals list, based on results from the Leapfrog Hospital Quality and Safety Survey, a national rating system that offers a broad assessment of a hospital?s quality and safety.

Nutrition :: Mandatory Fortification with Folic acid – Australia

All Ministerial Council members reinforced their commitment to reduce the number of neural tube defects through mandatory fortification with folic acid as quickly as possible. The Ministerial Council discussed the Final Assessment Report from Food Standards Australia New Zealand on a proposal for consideration of mandatory fortification of food with folic acid.

Asthma :: Bronchial thermoplasty reduces asthma attacks

The removal of muscle tissue in the hyperactive airways of asthma patients by exposing the tissue to heat reduces disease exacerbations and significantly improves the patients’ quality of life.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

ADHD :: Lisdexamfetamine dimesylate in ADHD phase 3 data presented

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that their investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX), yielded a 60 percent improvement in the primary rating scale scores for symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 years who received six months of treatment in an open-label phase III study. Results also demonstrated that at 6 months, 95 percent of children taking lisdexamfetamine dimesylate (NRP104/LDX) produced a “much improved” or “very much improved” rating on the Clinical Global Impressions ? Improvement score. These results were presented last weekend at a national meeting of child and adolescent psychiatrists.

Ulcerative Colitis :: Mesalamine associated with rapid mucosal healing in ulcerative colitis patients

Combined data analysis from two trials demonstrated that treatment success is associated with mucosal healing in patients with moderately active ulcerative colitis who received either 2.4 or 4.8 grams of mesalamine per day. By 6 weeks, 67% of patients achieved both treatment success and mucosal healing, while only 5% achieved treatment success without demonstrating mucosal healing. The results were presented by University of Chicago researcher David T. Rubin, MD, at the annual scientific meeting of the American College of Gastroenterology (ACG).

Crohn’s Disease :: Promising results in tough-to-treat crohn’s disease patients

Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.

Imaging :: Tripath imaging receives fda 510(k) clearance for p53 application for ventana image analysis system

TriPath Imaging Inc. (Nasdaq: TPTH) and Ventana Medical Systems, Inc. (Nasdaq: VMSI), announced today that TriPath Imaging has received 510(k) clearance from the U.S. Food and Drug Administration for the Ventana Image Analysis System (VIAS(TM)) when used with tissues stained for p53. In 2005 and 2006, the Companies announced 510(k) clearances for VIAS when used with the Ventana Estrogen Receptor (ER), Progesterone Receptor (PR), Ki-67 and HER- 2/neu assays.